Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis - Takeaways - MDSpire

Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis

  • By

  • Mariusz Ciołkiewicz

  • Anna Kuryliszyn-Moskal

  • Ewa Jabłońska

  • Wioletta Ratajczak-Wrona

  • Jacek Janica

  • Włodzimierz Samborski

  • Piotr A. Klimiuk

  • May 29, 2026

  • 0 min

Share

  • 1

    Approximately one-third of rheumatoid arthritis patients were found to have metabolic dysfunction-associated steatotic liver disease (MASLD).

  • 2

    The fatty liver index (FLI) and fatty acid binding protein 4 showed the best diagnostic performance for MASLD in rheumatoid arthritis patients.

  • 3

    FLI was positively associated with cardiovascular risk scores and left ventricular diastolic dysfunction parameters.

  • 4

    The neutrophil-to-lymphocyte ratio was significantly associated with an increased risk of MASLD in the study population.

  • 5

    Further investigation of organokines like FABP4 and FGF21 as biomarkers for MASLD is suggested due to their associations with liver-related measures.

Original Source(s)

Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis

  • by Mariusz Ciołkiewicz, Anna Kuryliszyn-Moskal, Ewa Jabłońska, Wioletta Ratajczak-Wrona, Jacek Janica, Włodzimierz Samborski, Piotr A. Klimiuk

  • May 29, 2026

Related Content

A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy

Denosumab in osteoarthritis: from mechanism to clinical translation

Deviation from physiologically appropriate oxygen levels alters proliferation, cytokine production and proximal antigen receptor signalling in CD4+ memory T cells